Xilio Therapeutics, Inc. financial data

Symbol
XLO on Nasdaq
Location
828 Winter Street, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 217 % +4.4%
Debt-to-equity 1.52K % +832%
Return On Equity -858 % -299%
Return On Assets -52.9 % +35.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52.5M shares +19.4%
Common Stock, Shares, Outstanding 51.8M shares +17.9%
Entity Public Float 41.5M USD -38.7%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 144M shares +127%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 19.1M USD +743%
Research and Development Expense 46.8M USD +5.99%
General and Administrative Expense 28.8M USD +16.9%
Operating Income (Loss) -43.8M USD +32.7%
Nonoperating Income (Expense) -14.7M USD -745%
Net Income (Loss) Attributable to Parent -58.5M USD +6.87%
Earnings Per Share, Basic 0 USD/shares +73.3%
Earnings Per Share, Diluted 0 USD/shares +73.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 104M USD +69.4%
Assets, Current 124M USD +96%
Property, Plant and Equipment, Net 3.68M USD -24.1%
Operating Lease, Right-of-Use Asset 4.13M USD -12.8%
Other Assets, Noncurrent 92K USD -53.3%
Assets 134M USD +79.1%
Accounts Payable, Current 2.3M USD +137%
Accrued Liabilities, Current 8.95M USD -8.59%
Liabilities, Current 56.4M USD +48.3%
Operating Lease, Liability, Noncurrent 5.96M USD -17.9%
Other Liabilities, Noncurrent 7K USD -91.5%
Liabilities 142M USD +164%
Retained Earnings (Accumulated Deficit) -429M USD -15.8%
Stockholders' Equity Attributable to Parent -8.1M USD -139%
Liabilities and Equity 134M USD +79.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 29M USD
Net Cash Provided by (Used in) Financing Activities 4.83M USD +406%
Net Cash Provided by (Used in) Investing Activities -22K USD
Common Stock, Shares Authorized 600M shares +200%
Common Stock, Shares, Issued 51.8M shares +17.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 33.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 106M USD +67.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 62K USD -70.3%
Deferred Tax Assets, Valuation Allowance 113M USD +21%
Deferred Tax Assets, Gross 115M USD +19.8%
Operating Lease, Liability 8.14M USD -11.4%
Depreciation 300K USD -25%
Payments to Acquire Property, Plant, and Equipment 22K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -58.5M USD +6.87%
Lessee, Operating Lease, Liability, to be Paid 9.99M USD -14.8%
Property, Plant and Equipment, Gross 12.1M USD +1.97%
Operating Lease, Liability, Current 1.3M USD +13.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.84M USD +3.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.79M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.84M USD -27.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.89M USD +2.99%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.95M USD +3.01%
Additional Paid in Capital 421M USD +7.51%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 497K USD +12.2%
Deferred Tax Assets, Net of Valuation Allowance 2.46M USD -17.5%
Share-based Payment Arrangement, Expense 5.53M USD -19.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%